Ambrosia Biosciences: Series BDevelops orally delivered, small molecule-based therapies for obesity and other metabolic disordersOct 4, 2026RoundOSAmbrosia BiosciencesCompany profile and funding historySourcesprnewswire.comMore in BiotechAusperBio · Series CProFound Therapeutics · StrategicTransfyr · SeedAIBiotechUnited StatesHealthtechNorth AmericaSeries B